Home/Pipeline/Intravenous Immunoglobulin (IVIG)

Intravenous Immunoglobulin (IVIG)

Primary & Secondary Immunodeficiencies, Autoimmune Diseases

MarketedActive

Key Facts

Indication
Primary & Secondary Immunodeficiencies, Autoimmune Diseases
Phase
Marketed
Status
Active
Company

About Shanghai RAAS Blood Products

Shanghai RAAS's mission is to ensure a stable, safe, and sufficient supply of plasma-derived therapeutics for the Chinese market, serving as a cornerstone of national biosecurity. The company has achieved a leading market position through strategic vertical integration, operating one of the largest networks of plasma collection stations and state-of-the-art fractionation facilities in the country. Its strategy is anchored in scaling plasma collection, expanding its high-value product portfolio (particularly immunoglobulins and factor concentrates), and maintaining technological leadership in viral safety and yield optimization. RAAS is poised for sustained growth driven by rising clinical demand, favorable reimbursement policies, and China's strategic push for plasma product self-sufficiency.

View full company profile